Cellectis S.A. - ADR (ZVAA)
XBER 
Summary
Cellectis' Allogeneic CAR-T Potential Still Justifies A 'Buy'
CELLS develops off-the-shelf TALEN-edited CAR-T therapies. Its main in-house asset is lasme-cel for r/r B-ALL and eti-cel for r/r B-cell NHL. Early data show that lasme-cel reached impressive ORRs in Phase 1, and CLLS should give us a pivotal Phase 2 readout expected in 2026. CLLS also has partnerships with big pharma companies like Allogene, Servier, Iovance, and AstraZeneca that should provide added optionality.
Cellectis S.A. (CLLS) Q2 2025 Earnings Call Transcript
Cellectis S.A. (NASDAQ:CLLS ) Q2 2025 Earnings Conference Call August 5, 2025 8:00 AM ET Company Participants Adrian Kilcoyne - Chief Medical Officer Andre Choulika - Co-Founder, CEO & Director Arthur Stril - CFO & Chief Business Officer Conference Call Participants Anqi Yu - Jefferies LLC, Research Division Huidong Wang - Barclays Bank PLC, Research Division Jack Kilgannon Allen - Robert W.
Cellectis: Partnerships And Promised Data In 2025 Continue To Justify The Buy
Cellectis SA's pipeline consists of allogeneic CAR T-cell therapies that have the potential to make meaningful dents in heme malignancies. The financial picture remains strong, bolstered further by a partnership with AstraZeneca. Promised data readouts in late 2025 represent important potential catalysts.
Cellectis S.A. - ADR (ZVAA) FAQ
What is the stock price today?
On which exchange is it traded?
What is its stock symbol?
Does it pay dividends? What is the current yield?
What is its market cap?
When is the next earnings date?
Has Cellectis S.A. - ADR ever had a stock split?
Cellectis S.A. - ADR Profile
| Biotechnology Industry | Healthcare Sector | Andre Choulika CEO | XBER Exchange | US15117K1034 ISIN |
| FR Country | 216 Employees | - Last Dividend | - Last Split | 7 Feb 2007 IPO Date |
Overview
Cellectis S.A. is a pioneering clinical-stage biotechnological company focused on the development of innovative immuno-oncology products. Leveraging gene-edited T-cells equipped with chimeric antigen receptors, the company aims at specifically targeting and destroying cancer cells. Founded in 1999 and with its headquarters in Paris, France, Cellectis is at the forefront of using gene-editing technology to create allogeneic (donor-derived) T-cell therapies for a range of hematologic malignancies and solid tumors. The company has forged strategic alliances with notable entities including Allogene Therapeutics, Inc., Les Laboratoires Servier, Iovance Biotherapeutics, Cytovia, and AstraZeneca to accelerate the development and commercialization of its cell and gene therapy products.
Products and Services
- UCART19: A flagship allogeneic T-cell product candidate designed for the treatment of acute lymphoblastic leukemia and other CD19-expressing hematologic malignancies. UCART19 utilizes gene-edited T-cells to target CD19, a protein common in certain types of leukemia.
- ALLO-501 and ALLO-501A: These products target relapsed or refractory non-Hodgkin lymphoma (NHL), employing modified T-cells to target cancer cells more effectively.
- ALLO-715: Aimed at treating multiple myeloma, ALLO-715 represents Cellectis' commitment to expanding its immuno-oncology portfolio to include therapies for a broader range of cancers.
- UCART22: This product is being developed to treat B-cell acute lymphoblastic leukemia, showcasing Cellectis’ specialized approach towards engineering T-cells to fight specific cancer types.
- UCARTCS1 and ALLO-605: Both focused on the treatment of multiple myeloma, these advanced therapy candidates demonstrate Cellectis' innovative approach to targeting and eradicating cancer cells through precision medicine.
- ALLO-316: Targeting renal cell carcinoma, ALLO-316 is designed to redirect T-cells to target and eliminate cancer cells, highlighting Cellectis’ push into solid tumors.
- UCART123: Focused on acute myeloid leukemia, UCART123 represents a cutting-edge approach to treating this challenging and relatively common form of leukemia.
- UCART 20x22: Developed for the treatment of relapsed or refractory B-Cell non-Hodgkin lymphoma, this product features a dual targeting approach to enhance the specificity and efficiency of cancer cell eradication.
Through these developments, Cellectis S.A. demonstrates a robust pipeline designed to leverage the power of gene editing and T-cell therapy to create more effective and targeted cancer treatments. The company’s strategic collaborations and research efforts underscore its commitment to advancing the field of immuno-oncology and offering new hope to patients worldwide.
Contact Information
